<p>Elon Musk's brain chip startup Neuralink has raised $280 million in a funding round led by Peter Thiel's Founders Fund, months after securing approval for its first in-human clinical trial.</p>.<p>The company did not reveal the valuation at which the funds were raised. In June, <em>Reuters</em> reported that the company was valued at about $5 billion after privately executed stock trades.</p>.BioNTech reduces drug development spend as Covid shot sales plunge.<p>"We're extremely excited about this next chapter at Neuralink," the company said in a post on Musk-owned social media platform X, formerly known as Twitter.</p>.<p>Neuralink employees told <em>Reuters</em> last year the company was rushing and botching surgeries on monkeys, pigs and sheep, resulting in more animal deaths than necessary, as Musk pressured staff to receive FDA approval.</p>.<p>The animal experiments produced data intended to support the company's application for human trials, the sources said.</p>.<p>In May, US lawmakers urged regulators to investigate whether the makeup of a panel overseeing animal testing at Neuralink contributed to botched and rushed experiments after Reuters reported on potential financial conflicts on the panel.</p>
<p>Elon Musk's brain chip startup Neuralink has raised $280 million in a funding round led by Peter Thiel's Founders Fund, months after securing approval for its first in-human clinical trial.</p>.<p>The company did not reveal the valuation at which the funds were raised. In June, <em>Reuters</em> reported that the company was valued at about $5 billion after privately executed stock trades.</p>.BioNTech reduces drug development spend as Covid shot sales plunge.<p>"We're extremely excited about this next chapter at Neuralink," the company said in a post on Musk-owned social media platform X, formerly known as Twitter.</p>.<p>Neuralink employees told <em>Reuters</em> last year the company was rushing and botching surgeries on monkeys, pigs and sheep, resulting in more animal deaths than necessary, as Musk pressured staff to receive FDA approval.</p>.<p>The animal experiments produced data intended to support the company's application for human trials, the sources said.</p>.<p>In May, US lawmakers urged regulators to investigate whether the makeup of a panel overseeing animal testing at Neuralink contributed to botched and rushed experiments after Reuters reported on potential financial conflicts on the panel.</p>